X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. It is being evaluated in combination with venetoclax for the treatment of higher-risk myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Decitabine,Cedazuridine,Venetoclax
Therapeutic Area: Oncology Product Name: Inqovi
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Truqap, a first-in-class AKT inhibitor, discovered by AstraZeneca subsequent to its collaboration with Astex, recently approved by FDA in combination with Faslodex, for treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $275.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 22, 2023
Details:
Truqap (capivasertib), a first in class, oral targeted inhibitor of the cancer-driving protein AKT, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $275.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 20, 2023
Details:
Inaqovi (decitabine and cedazuridine) is an orally administered, fixed-dose combination and inhibitor of cytidine deaminase, which is indicated for newly diagnosed acute myeloid leukaemia.
Lead Product(s): Cedazuridine,Decitabine
Therapeutic Area: Oncology Product Name: Inaqovi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Otsuka Holdings
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Under the collaboration, Astex will apply its fragment-based drug discovery platform to develop small molecule candidates targeting multiple forms of the p53 tumour suppressor protein for the treatment of cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $535.0 million Upfront Cash: $35.0 million
Deal Type: Expanded Collaboration August 08, 2023
Details:
Under the terms of the agreement, scientists at the MDI and Astex will collaborate to carry out drug discovery research against a chosen lysosomal target with the aim to identify and optimise compounds that modulate its activity to treat neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Cardiff University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2023
Details:
AZD 5363 (capivasertib) is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for haematologic malignancies.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: AZD 5363
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
ASTX727 is an orally administered, fixed dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine, an inhibitor of cytidine deaminase.
Lead Product(s): Decitabine,Cedazuridine
Therapeutic Area: Oncology Product Name: ASTX727
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
In new exploratory analysis of data from MONALEESA-2 study, Kisqali (ribociclib) plus letrozole maintained an OS benefit for postmenopausal patients with metastatic breast cancer treated in first-line, including for those patients who required dose modification of Kisqali.
Lead Product(s): Ribociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
ASCERTAIN - AML clinical study of decitabine and cedazuridine, as a fixed-dose combination (ASTX727), in adult patients with AML not candidates for chemotherapy demonstrated decitabine exposure equivalence of total 5-day dosing between oral ASTX727 and intravenous decitabine.
Lead Product(s): Decitabine,Cedazuridine
Therapeutic Area: Oncology Product Name: ASTX727
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
